4-tert-butyl-N-[6-chloro-5-(o-methoxyphenoxy)-4-pyrimidinyl]-benzene sulfonamide | 150727-24-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-tert-butyl-N-[6-chloro-5-(o-methoxyphenoxy)-4-pyrimidinyl]-benzene sulfonamide
• 英文别名: p-t-butyl-N-[6-chloro-5-(o-methoxyphenoxy)-4-pyrimidinyl]benzenesulfonamide；4-tert.-butyl-N-[6-chloro-5-(o-methoxyphenoxy)-4-pyrimidinyl]-benzene sulfonamide；4-tert-butyl-N-[6-chloro-5-(2-methoxyphenoxy)-4-pyrimidinyl]benzenesulfonamide；p-t-butyl-N-[6-chloro-5-(o-methoxyphenoxy)-4-pyrimidinyl]benzene-sulfonamide；4-tert-butyl-N-[6-chloro-5-(2-methoxyphenoxy)pyrimidin-4-yl]benzenesulfonamide
• CAS: 150727-24-5
• 化学式: C₂₁H₂₂ClN₃O₄S
• 分子量: 447.942
• InChiKey: GLCKDDGHXHWQFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  98.8
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-tert-butyl-N-[6-chloro-5-(o-methoxyphenoxy)-4-pyrimidinyl]-benzene sulfonamide 在 sodium hydride 、 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 反应 8.5h， 生成 4-tert-butyl-N-[5-(2-methoxyphenoxy)-6-(4-oxobutoxy)pyrimidin-4-yl]benzenesulfonamide
  参考文献：
  名称：

  Synthesis and structure–activity relationships of potent and orally active sulfonamide ETB selective antagonists

  摘要：

  The synthesis and structure-activity relationships of a series of N-pyrimidinyl benzenesulfonamides as ETB selective antagonists are described. N-Isoxazolyl benzenesulfonamide 1a. previously reported,(1) was selected as a lead compound, and isosteric replacement of the isoxazole ring of la with a pyrimidine ring led to the discovery of the highly potent ETB selective antagonist 6e with oral bioavailability. Modification of the terminal aldehyde group at the 6-position of the pyrimidine ring was investigated, and malonate 15b and acylhydrazone 16f were found to be equipotent to aldehyde 6e. Compound 6e showed ETB antagonistic activity on in vivo evaluation. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00305-9
• 作为产物：
  描述：

  2-(2-甲氧基苯氧基)丙二酸二甲酯 在 2,3,5-三甲基吡啶 、 sodium methylate 、 三氯氧磷 作用下， 以 甲醇 、 二甲基亚砜 为溶剂， 反应 7.0h， 生成 4-tert-butyl-N-[6-chloro-5-(o-methoxyphenoxy)-4-pyrimidinyl]-benzene sulfonamide
  参考文献：
  名称：

  Synthesis and structure–activity relationships of potent and orally active sulfonamide ETB selective antagonists

  摘要：

  The synthesis and structure-activity relationships of a series of N-pyrimidinyl benzenesulfonamides as ETB selective antagonists are described. N-Isoxazolyl benzenesulfonamide 1a. previously reported,(1) was selected as a lead compound, and isosteric replacement of the isoxazole ring of la with a pyrimidine ring led to the discovery of the highly potent ETB selective antagonist 6e with oral bioavailability. Modification of the terminal aldehyde group at the 6-position of the pyrimidine ring was investigated, and malonate 15b and acylhydrazone 16f were found to be equipotent to aldehyde 6e. Compound 6e showed ETB antagonistic activity on in vivo evaluation. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00305-9

文献信息

• The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists
  作者：Martin H Bolli、Christoph Boss、Martine Clozel、Walter Fischli、Patrick Hess、Thomas Weller

  DOI：10.1016/s0960-894x(02)01084-3

  日期：2003.3

  A series of compounds structurally related to bosentan 1 featuring an unsaturated side chain at position 6 of the core pyrimidine have been studied for their potential to block the ET(A) and ET(B) receptor. Incorporation of a 2-butyne-1,4-diol linker bearing a pyridyl carbamoyl moiety led to in vitro highly potent endothelin receptor antagonists (e.g., 70 and 75). The propargyl derivative 26 significantly

  研究了一系列与波生丹1结构相关的化合物，这些化合物在嘧啶核的6位上具有不饱和侧链，具有阻断ET（A）和ET（B）受体的潜力。掺入带有吡啶基氨基甲酰基部分的2-丁炔-1，4-二醇接头导致体外高效的内皮素受体拮抗剂（例如70和75）。在高血压盐敏感性Dahl大鼠的体内模型研究中，炔丙基衍生物26显着降低了血压。
• Butyne diol derivatives
  申请人：——

  公开号：US20030087920A1

  公开（公告）日：2003-05-08

  The present invention relates to novel butyne diol derivatives of the general formula I and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula I and especially their use as endothelin receptor antagonists.

  本发明涉及一般式I的新型丁炔二醇衍生物及其在制备药物组合物中作为活性成分的用途。该发明还涉及相关方面，包括制备化合物的过程、含有一种或多种一般式I化合物的药物组合物，特别是它们作为内皮素受体拮抗剂的用途。
• Sulfonamides
  申请人：Hoffmann-La Roche Inc.

  公开号：US05292740A1

  公开（公告）日：1994-03-08

  The novel sulfonamides of formula I, ##STR1## in which the symbols R.sup.1 -R.sup.9, R.sup.a, R.sup.b, X, Y and n have the significance given in the description and salts thereof can be used for the treatment of circulatory disorders, especially hypertension, ischemia, vasopasms and angina pectoris.

  化学式I的新磺胺类化合物，##STR1## 其中符号R.sup.1 -R.sup.9，R.sup.a，R.sup.b，X，Y和n的含义如描述中所示，以及其盐可用于治疗循环系统疾病，特别是高血压、缺血、血管痉挛和心绞痛。
• PROCESSES FOR THE PREPARATION OF BOSENTAN AND ITS INTERMEDIATES THEREOF
  申请人：Yadav Roop Singh

  公开号：US20100256371A1

  公开（公告）日：2010-10-07

  The present invention relates to processes for the preparation of bosentan and compounds that can be used as structurally novel intermediates for the synthesis thereof, and a pharmaceutical composition of the same.

  本发明涉及用于制备博瑟坦和可用作其合成的结构新型中间体的过程，以及相应的药物组合物。
• PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN)
  申请人：Joshi Shreerang

  公开号：US20120136015A1

  公开（公告）日：2012-05-31

  The present invention relates to processes for the preparation of an endothelial receptor antagonist. The present invention particularly relates to synthesis of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzene sulfonamide (bosentan).

  本发明涉及制备内皮受体拮抗剂的方法。本发明特别涉及4-叔丁基-N-[6-(2-羟基乙氧基)-5-(2-甲氧基苯氧基)-2-(2-嘧啶基)-4-嘧啶基]苯磺酰胺（博生坦）的合成。